<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242096</url>
  </required_header>
  <id_info>
    <org_study_id>SI-ISR-01</org_study_id>
    <nct_id>NCT03242096</nct_id>
  </id_info>
  <brief_title>Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon</brief_title>
  <official_title>Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated SEQUENT® SCB RAPID EXCHANGE PTCA Balloon Catheter or a Paclitaxel Coated SEQUENT® PLEASE PTCA Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of coronary in-stent restenosis (ISR) by a sirolimus coated SEQUENT® SCB RAPID
      EXCHANGE PTCA balloon catheter or a paclitaxel coated SEQUENT® PLEASE PTCA balloon catheter
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental intervention: Predilatation of coronary ISR with POBA followed by a sirolimus
      coated SeQuent®SCB balloon balloon (sirolimus 4.0 μg/mm²)

      Control intervention: Predilatation of coronary ISR with POBA followed by a paclitaxel coated
      SeQuent®Please balloon or SeQuent®Please NEO balloon (paclitaxel 3.0 μg/mm²)

      Duration of intervention per patient: minutes

      Follow-up per patient: 30 days telephone call; 6 months angiographic + 12 months clinical
      follow up
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental intervention: Predilatation of coronary ISR with POBA followed by a sirolimus coated SeQuent® SCB balloon balloon (sirolimus 4.0 μg/mm²)
Control intervention: Predilatation of coronary ISR with POBA followed by a paclitaxel coated SeQuent® Please balloon or SeQuent® Please NEO balloon (paclitaxel 3.0 μg/mm²)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded QCA for primary outcome</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss in-lesion at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>late lumen loss in-lesion at 6 months assessed by blinded QCA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>during hospital stay of index procedure</time_frame>
    <description>&lt; 30% final stenosis, TIMI III flow, no flow-limiting dissection, and the absence of in-hospital MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual clinical endpoints</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>stent thrombosis, cardiac death, target lesion myocardial infarction, clinically driven target lesion revascularization, binary restenosis (stenosis ≥ 50% at follow-up angiography)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Sirolimus coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of in-stent restenosis with a sirolimus coated balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel coated balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of in-stent restenosis with a paclitaxel coated balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sirolimus coated balloon</intervention_name>
    <description>Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)</description>
    <arm_group_label>Sirolimus coated balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Paclitaxel coated balloon</intervention_name>
    <description>Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)</description>
    <arm_group_label>Paclitaxel coated balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Clinical evidence of stable or unstable angina (acute coronary syndrome) or a positive
             functional study

          -  Patients with ≤ 2 primary in-stent restenosis (ISR) lesions (≥ 70% diameter stenosis
             by visual estimation or ≥50% and positive functional study) including margin-stenosis
             with max 5 mm distance to the stent

        Exclusion Criteria:

          -  Chronic renal insufficiency with serum creatinine levels &gt; 2.0 mg per deciliter

          -  Known hypersensitivity or contraindications to aspirin, heparin, clopidogrel,
             ticlopidine or sirolimus, and sensitivity to contrast media not amenable to
             premedication

          -  Concomitant medical illness associated with a life-expectancy of less than two year

          -  Lesion length (ISR) &gt; 35 mm, reference vessel diameter &lt; 2.5 mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Scheller, MD</last_name>
    <phone>+49 6841 1615927</phone>
    <email>bruno.scheller@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical and Experimental Interventional Cardiology</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Scheller, MD</last_name>
      <phone>+49 6841 1615927</phone>
      <email>bruno.scheller@uks.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>August 5, 2017</last_update_submitted>
  <last_update_submitted_qc>August 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

